Biktarvy is not approved for PrEP and should not be used for that purpose. It is a three-drug combination pill designed to treat HIV in people who already have the virus. While Biktarvy shares two of its ingredients with an approved PrEP medication, it contains an additional drug that is unnecessary for prevention and introduces risks if taken by someone who is HIV-negative.
What Biktarvy Actually Is
Biktarvy is a single daily tablet containing three active drugs: bictegravir, emtricitabine, and tenofovir alafenamide. It’s prescribed as a complete treatment regimen for people living with HIV. In long-term studies following patients for five years, the combination proved highly effective at suppressing the virus.
Two of those three ingredients, emtricitabine and tenofovir alafenamide, are the same drugs found in Descovy, which is an FDA-approved PrEP medication. The difference is bictegravir, an integrase inhibitor that blocks HIV from inserting its genetic material into human cells. That third drug is essential for treating an active infection but serves no approved role in prevention.
The Three FDA-Approved PrEP Options
Only three medications are currently approved by the FDA for pre-exposure prophylaxis:
- Truvada (or generic equivalents): a daily pill combining emtricitabine and tenofovir disoproxil fumarate. Recommended for all people at risk through sex or injection drug use.
- Descovy: a daily pill combining emtricitabine and tenofovir alafenamide. Recommended for sexual transmission prevention, but not for people at risk through receptive vaginal sex, as it hasn’t been studied in that group.
- Apretude: an injectable form of cabotegravir given every two months. Recommended for preventing sexual transmission in all people.
Biktarvy is not on this list. No integrase inhibitor-based combination has been approved for PrEP in pill form.
Why Biktarvy Is Used for PEP, Not PrEP
There’s an important distinction that causes some of the confusion around this topic. PrEP is medication taken on an ongoing basis before potential exposure to HIV. PEP (post-exposure prophylaxis) is a short course of medication taken after a possible exposure, typically started within 72 hours and continued for 28 days.
Biktarvy is now one of the CDC’s preferred regimens for PEP. Updated 2025 guidelines list it as a first-line option for adults and adolescents who need post-exposure treatment. A Boston study of 52 adults who took Biktarvy as PEP found that all participants remained HIV-negative at two-month follow-up, and 90% completed the full 28-day course. Side effects were relatively mild: 15% experienced nausea or vomiting, 10% had fatigue, and 8% reported diarrhea. Researchers noted it was better tolerated than older PEP regimens.
PEP requires a full three-drug treatment regimen because the goal is to stop a virus that may have already entered the body. PrEP works differently. It builds up protective drug levels in tissue before any exposure occurs, and two-drug combinations have proven sufficient for that task in large clinical trials.
Why Taking Biktarvy as PrEP Could Be Harmful
Using a three-drug HIV treatment as prevention creates a specific medical risk. If someone taking Biktarvy as unofficial PrEP were to acquire HIV without realizing it, the situation becomes complicated. Integrase inhibitors like bictegravir can drive resistance mutations in the virus if the infection isn’t detected quickly. Cases of integrase inhibitor resistance have already been documented in people who acquired HIV while using injectable cabotegravir for PrEP.
When resistance develops, it limits future treatment options. Guidelines now recommend that anyone who acquires HIV after exposure to an integrase inhibitor should have specialized resistance testing done before starting a treatment regimen. In some cases, clinicians are advised to avoid integrase inhibitor-based treatment entirely until those test results come back.
PrEP with Truvada or Descovy avoids this problem. Those two-drug combinations don’t include an integrase inhibitor, so even if someone does acquire HIV while on PrEP, the full range of treatment options typically remains available.
Transitioning From PEP to PrEP
If you’ve recently taken Biktarvy as PEP and want ongoing protection, CDC guidelines recommend creating a transition plan with your provider. The process involves completing your 28-day PEP course, getting tested to confirm you’re HIV-negative, and then promptly starting one of the three approved PrEP options. An immediate transition is encouraged for anyone with anticipated repeat or ongoing exposure to HIV, so there’s no gap in protection between finishing PEP and beginning PrEP.
Choosing the Right PrEP Option
Your PrEP choice depends on your circumstances and preferences. Truvada and its generics offer the broadest recommendation, covering both sexual and injection drug use exposure for all people regardless of gender. Generic versions have also made it the most affordable option for many. Descovy uses a newer form of tenofovir that may be easier on the kidneys and bones, but its approval doesn’t extend to people at risk through receptive vaginal sex. Apretude, the injectable, eliminates the need for a daily pill entirely, requiring only a clinic visit every two months after an initial loading period.
All three approved PrEP options are highly effective when used as directed. The best choice is the one you’ll actually use consistently.